Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

The folks be­hind Atom­wise’s spin­out X-37 like to think in cos­mo­log­i­cal metaphors, and you can think of their AI drug de­vel­op­ment mod­el as probes sent in­to space from a cen­tral sta­tion. That sta­tion just got $14.5 mil­lion in Se­ries A fund­ing from DCVC Bio, Al­pha In­tel­li­gence Cap­i­tal and He­mi Ven­tures to back those mis­sions.

X-37 us­es Atom­wise’s AI plat­form to iden­ti­fy drug tar­gets and – un­like the par­ent com­pa­ny, which large­ly sticks to com­put­ers  – bring those in­to a wet lab and pre­clin­i­cal test­ing.  In ad­di­tion to AI pro­fes­sion­als, it’s led in by part by drug de­vel­op­ers from Ve­loc­i­ty Phar­ma­ceu­ti­cal De­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER